As a first step towards elucidating the potential role(s) of bcl-2 and bcl-2-related genes in lung tumorigenesis and therapeutic responsiveness, the expression of these genes has been examined in a panel of lung cancer cell lines derived from untreated and treated patients, and in cell lines selected in vitro for multidrug resistance. Bcl-2 was hyperexpressed in 15 of 16 small-cell lung cancer (SCLC) cell lines and two of five non-small-cell lung cancer (NSCLC) lines compared with normal lung and brain, and hyperexpression was not chemotherapy related. Bcl-x was hyperexpressed in the majority of SCLC and NSCLC cell lines as compared with normal tissues, and all lung tumour lines preferentially expressed bcl-xl-mRNA, the splice variant form that inhibits apoptosis. Bax gene transcripts were hyperexpressed in most SCLC and NSCLC cell lines examined compared with normal adult tissues. Mutant p53 gene expression was detected in the majority of the cell lines and no relationship between p53 gene expression and the expression of either bcl-2, bcl-x or bax was observed. No changes in bcl-2, bcl-x and bax gene expression were observed in multidrug-resistant cell lines compared with their drug-sensitive counterparts.
Recent evidence suggests that the genetic regulation of apoptosis involves a complex interplay between certain oncogenes, p53, bcl-2 and bcl-2-related proteins, and that subversion of this process, through mutation or altered expression of these genes, is of fundamental importance during tumorigenesis (McDonnell, 1993; Williams and Smith, 1993) . Thus, mutation of the p53 tumour-suppressor gene, which occurs frequently in tumours (Hollstein et al., 1991) , results in loss of p53 function in inducing apoptosis in a cell type-and stimulus-specific manner. t(14:18) chromosomal translocation resulting in the juxtaposition of the immunoglobulin heavy-chain gene with the bcl-2 gene, which functions in enhancing cell survival through its ability to suppress apoptosis (for review see Reed, 1994) , results in transcriptional deregulation and abnormally high levels of bcl-2 protein, and is a critical event in the molecular pathogenesis of the majority of human B-cell follicular lymphomas. In addition to lymphomas with the t(14:18) translocation, high levels of bcl-2 protein and/or aberrant patterns of bcl-2 protein production have been described in a wide variety of human tumours, including many leukaemias, neuroblastomas and other tumours of neural origin, and in carcinomas of the lung, prostate, colon and nasopharynx (Campos et al., 1993; Reed et al., 1991; McDonnell et al., 1992; Pezzella et al., 1993; Lu et al., 1993) . As there is little or no evidence for gross alterations in bcl-2 gene structure in these cancers, the frequent hyperexpression of bcl-2 in such tumours may indicate the existence of other genetic mechanisms for dysregulation of bcl-2 gene expression. Interestingly, recent studies have shown that the wild-type p53 tumour-suppressor gene product can inhibit bcl-2 expression through its interaction with a p53-dependent negative response element in the bc1-2 gene (Miyashita et al., 1994a,b) . This raises the possibility that p53 gene inactivation may account for the widespread hyperexpression of bcl-2 in tumours. Although, at present, there are few data on the expression in tumours of the bcl-2-related genes bcl-x and bax, the roles played by these genes in the regulation of apoptosis suggest their likely involvement in tumour development. Bcl-x has been shown to be involved in both positive and negative regulation of apoptosis (Boise et al., 1993) . Alternative splicing results in two distinct bcl-x mRNA species, namely bcl-x, and bcl-x,. Whereas bcl-xl inhibits cell death upon growth factor withdrawal, bcl-x, encodes a protein that increases the dependence of cells on growth factors to prevent cell death and, importantly, inhibits the ability of bcl-2 to enhance the survival of growth factordeprived cells. Thus, bcl-x plays a major role in regulating the dependence of cells on continuous exogenous signals to prevent cell death, raising the possibility that altered regulation of bcl-x expression or of mRNA splicing could confer autonomous cell survival potential and contribute to tumour development. In addition to bcl-xs, bcl-2 has been shown to be modified in its function by bax, which accelerates apoptosis (Oltvai et al., 1993) . The bax gene product heterodimerises with, and inactivates, bcl-2 protein, and it has been suggested that the ratio of bax to bcl-2 determines survival or death following an apoptotic signal.
Importantly, bax gene expression has also been shown to be regulated by wild-type p53 (Miyashita et al., 1994a) , but whereas p53 negatively regulates bcl-2 expression, it upregulates bax expression, suggesting that p53-induced alterations in bcl-2 and bax expression play a major role in p53-induced apoptosis. Although the effect of p53 inactivation on bax gene expression remains to be determined, it has been predicted that a low level of bax expression will occur in tumours showing p53 loss (Miyashita et al., 1994a) . This, in turn, might be expected to contribute indirectly to enhanced survival in such tumours via the release of bcl-2 protein from bax inhibition.
The intense interest in the genetic deregulation of apoptosis arises not only from its role in oncogenesis but also from the increasing realisation of the importance of apoptosis as a mechanism of cell death by anti-cancer drugs, radiation and other toxic pathways (Ohmori et al., 1993; Walton et al., 1993; Miyashita and Reed, 1992; Manome et al., 1993; Hennet et al., 1993) . Importantly, bcl-2 gene transfection has been shown to confer resistance to several anti-cancer drugs by a mechanism that does not involve classical drug resistance pathways such as drug transport or topoisomerase II expression (Fisher et al., 1993; Kamesaki et al., 1993 As a first step towards investigating the possible involvement of bcl-2, bcl-x, and bax in lung tumour development and the roles played by these genes in determining therapeutic responsiveness, the present study investigates the expression of bcl-2, bcl-x and bax together with p53 in small-cell lung cancer (SCLC) cell lines derived from untreated and pretreated patients, in non-small-cell lung cancer (NSCLC) cell lines and in SCLC and NSCLC cell lines selected in vitro for multidrug resistance.
Materials and methods Cells With the exception of NCI-H69 (donated by Drs D Carney and A Gazdar, National Cancer Institute Navy Medical Oncology Branch, Bethesda, MD, USA) and LUDLU-1 (supplied by Dr P H Rabbitts of this unit), all lung tumour cell lines used in this study were generous gifts from Dr P R Twentyman (of this unit). The derivation and characterisation of the cell lines COR-L24, -L42, -L47,-L51, -L88 and -L23, have been described previously (Baillie-Johnson et al., 1985) . COR-L96C, -1103, -L266, -L279, -L311, -L316 and -L321 were similarly derived from pathologically confirmed SCLC patients. Cell lines COR-L51, -L88, -L103, -L311, -L316 and -L321 were derived from SCLC patients receiving combination chemotherapy including etoposide, vincristine, methotrexate and cycloheximide. The derivation and characterisation of the multidrug-resistant variants of NCI-H69, MOR and COR-L23 are described in detail elsewhere (Twentyman et al., 1986) . COR-L105 and MOR were derived from a patient with a histological diagnosis of adenocarcinoma of the lung. The cell line BEN was derived from a squamous cell lung carcinoma. The B-cell lymphoma cell line DoHH2 (Cotter et al., 1994) (Boise et al., 1993) . Amplification for both sets of primers was performed as follows: (1) denaturation at 95°C for 2 min; (2) annealing at 60°C for 1 min; (3) extension at 720C for 1 min. Steps 1-3 were repeated 36 times with the exception that the final cycle extension was for 10 min at 72°C.
The amplification mixture was electrophoresed on a 1.4% agarose gel in the presence of ethidium bromide. The sizes of the amplification products were 382 bp (bax), 764 bp (bcl-x,) and 576 bp (bcl-x,) . The amplification products, detected by ultraviolet transillumination, were excised and 32p labelled using an oligolabelling kit (Amersham International).
RNA preparation and Northern blot analyses Cells in logarithmic phase of growth were collected by centrifugation at 300 g for 10 min and suspended in 100 jl of medium. A solution containing 6.0 M guanidine hydrochloride and 0.2 M sodium acetate (pH 5.5) was added to the cells (20 ml per 5 x 107 cells) and RNA was precipitated by the addition of a half volume of 95% ethanol followed by incubation at -20°C overnight. The pelleted precipitate was dissolved in a solution containing 7.0 M urea, 0.35 M sodium chloride, 50 mM Tris pH 7.5, 1 mM EDTA and 0.2% sodium dodecyl sulphate (SDS) and was extracted once with phenolchloroform. RNA was precipitated from the aqueous phase using two volumes of ethanol, washed with 70% ethanol, air dried and dissolved in sterile, double distilled water. Human brain and lung mRNA was obtained from Cambridge Bioscience, Cambridge, UK. Total RNA (10 jug) in 10 mM sodium phosphate buffer (pH 7.0) was denatured in 1.0 M glyoxal for 1 h at 50°C. The RNA was electrophoresed in a 1.4% agarose gel in 10 mM sodium phosphate buffer and was transferred by Northern blotting to nylon filters. After treatment for 2 min with ultraviolet light, the nylon filters were baked at 800C for 2 h before hybridisation to oligolabelled cDNA probes. For all Northern blot analyses, filters were probed with a mouse fiactin probe (PRT3) (kindly donated by Dr John Rogers, Laboratory of Molecular Biology, Cambridge, UK) to confirm approximately equal loading of RNA in all tracks.
Preparation of microsomal membranes and immunodetection of bcl-2 Crude membranes were prepared as described previously with minor modifications (Reeve et al., 1993) . Briefly, cells were removed from tissue culture flasks using a cell-scraper and were centrifuged at 300 x g for 4 min. The pellet was resuspended in ice-cold lysis buffer consisting of 10 mM Tris-HCl buffer (pH 7.4) containing 4 ,ug ml-' aprotinin, 4 jig ml-' leupeptin and 0.1 mM phenylmethylsulphonyl fluoride, and homogenised by passage through a 26 gauge syringe needle. The suspension was centrifuged at 450 x g for 10 min and the resulting supernatant further centrifuged at 50 000 x g for 1 h. The pellet was then resuspended in lysis buffer to a final protein concentration of approximately 5 mg ml-' and stored at -700C until assay.
Membrane proteins (100 jig) were electrophoresed on a 12.5% SDS-polyacrylamide gel under non-reducing conditions. Proteins were transferred to cellulose nitrate paper as described elsewhere (Reeve et al., 1993 Figure la . It can be seen that the bcl-2 cDNA probe detected a 8.5 kb transcript in all SCLC cell lines examined with the exception of COR-L279. Two smaller transcripts of 6.0 kb and 3.5 kb were also consistently detected in COR-L31 1, and the significance of this observation is currently under investigation. It Expression of apoptosis-regulatory genes in lung tumour cells JG Reeve et Figure la and lb that the levels of mRNA and protein expression in the different cell lines generally correlate well. However, the relative expression of bcl-2 mRNA in COR-L24 and COR-L51 does not appear to accord with that of bcl-2 protein in these two cell lines. (Figure 3b) showed no detectable p53 transcript when total RNA was used for analysis. However, a very low level of p53 gene expression was detected in these cell lines when mRNA was analysed (data not shown). The remaining cell lines showed varying levels of p53 gene expression and no relationship between the levels of p53, bcl-2 and bax gene expression was evident. Similarly, no relationship between the expression of these genes was observed in the NSCLC cell lines examined (data not shown). Table I ), and several show strong p53 immunostaining typical of mutant p53 (PH Rabbits, personal communication and J Xiong, unpublished results). Bcl-2 hyperexpression occurred in SCLC and NSCLC cell lines showing both low (e.g.-L316, MOR) and high levels (e.g.-L88, BEN) of mutant p53 gene expression and protein production, indicating in the latter cell lines a failure of mutant p53 protein to down-regulate bcl-2 gene expression. The discrepancy between the findings in lung and breast carcinomas cannot be attributed to differences in the nature of the p53 mutations since several of the mutations associated with bcl-2 down-regulation in breast cancer cells were also present in the lung tumour cell lines examined. Interestingly, it has been suggested that the magnitude of wild-type p53 suppression of bcl-2 expression may be tissue specific (Miyashita et al., 1994b) . Thus, the apparent difference in the suppressive effect of mutant p53 on bcl-2 expression seen in breast and lung tumour cells may reflect such tissue-specific effects and/or the existence of other unidentified factors which influence the regulation of the bcl-2 gene by p53. Notwithstanding the findings in breast tumour cells, it may be that the hyperexpression of bcl-2 in lung tumours reflects p53 gene inactivation in these cells, as has been suggested previously (Miyashita et al., 1994a) . However, the bcl-2-negative SCLC cell line bcl-2-negative NSCLC cell line LUDLU-1 express mutant and not wild-type p53, challenging a simple relationship between p53 inactivation and bcl-2 hyperexpression in lung tumour cells.
Studies in p53 knock-out mice have demonstrated that p53 increases bax expression and, on the basis of this finding, it has been suggested that p53 loss in human tumours will be associated with decreased bax expression (Miyashita et al., 1994a) . The findings of the present study show that p53 mutation is not associated with loss of bax expression. Indeed, the majority of lung tumour cell lines hyperexpressed bax compared with normal lung and brain. In marked contrast to the expression of bcl-2, which is considerably greater in SCLC than in the majority of NSCLC cells, no difference in the levels of bax gene expression in SCLC and NSCLC cell lines was observed. As it has been suggested previously that the ratio of bcl-2 to bax protein controls the relative susceptibility of certain cells to death stimuli (Oltvai et al., 1993) , the observed differences in the relative levels of bcl-2 and bax gene expression in SCLC and NSCLC cells may indicate differences in their susceptibility to apoptotic death.
Bcl-2 gene transfection studies in various neoplastic lymphoid cell lines and in human neuroblastoma cell lines have shown that elevation of the level of bcl-2 protein markedly increased resistance to a variety of chemotherapeutic drugs (Ohmori et al., 1993; Miyashita and Reed, 1992; Fisher et al., 1993; Kamesaki et al., 1993; Dole et al., 1994; Miyashita and Reed, 1993) . Conversely, bcl-2 antisense studies in which levels of bcl-2 were reduced significantly increased cellular sensitivity to these drugs (Kitada et al., 1994) . Such findings highlight the ability of bcl-2 to provide a mechanism for tumour cells to survive the cytotoxic effects of chemotherapy. In the present study, no change in the levels of bcl-2, bcl-x or bax gene expression were observed between the SCLC cell line COR-L24 derived from an untreated tumour that responded completely to subsequent chemotherapy and the cell line COR-103 derived from a recurrent tumour in this patient. Similarly, no increases in either bcl-2 or bcl-x gene expression were observed in the Pglycoprotein-positive multidrug-resistant SCLC cell lines or the P-glycoprotein-negative drug-resistant NSCLC lung tumour cell lines. As no resistance-related decrease in bax expression was observed in these cells, it is unlikely that bel-2, bcl-x and bax are mechanistically involved in the acquisition of in vitro multidrug resistance. However, it has been reported recently that transfection of the bcl-2 gene into a SCLC non-expressor resulted in increased resistance to chemotherapeutic agents including doxorubicin and mitomycin C (Ohmori et al., 1993) . Such findings suggest that changes in the relative expression of apoptosis regulatory genes may be a major determinant of drug sensitivity in lung tumour cells and indicate a therapeutic potential for treatment strategies that modulate the expression of the genes.
